Slate Path Capital LP Buys Shares of 319,000 NewAmsterdam Pharma (NASDAQ:NAMS)

Slate Path Capital LP acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 319,000 shares of the company's stock, valued at approximately $8,198,000. Slate Path Capital LP owned approximately 0.35% of NewAmsterdam Pharma as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NAMS. State Street Corp raised its holdings in NewAmsterdam Pharma by 168.7% during the 3rd quarter. State Street Corp now owns 37,915 shares of the company's stock worth $629,000 after purchasing an additional 23,805 shares during the last quarter. Barclays PLC increased its position in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after buying an additional 7,199 shares in the last quarter. Geode Capital Management LLC raised its stake in NewAmsterdam Pharma by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock worth $1,433,000 after buying an additional 1,399 shares during the period. JPMorgan Chase & Co. boosted its holdings in NewAmsterdam Pharma by 176.9% in the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $224,000. 89.89% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director James N. Topper purchased 1,135 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the purchase, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at approximately $305,550. This trade represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. Finally, Scotiabank increased their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Stock Up 0.3 %

NewAmsterdam Pharma stock traded up $0.05 during mid-day trading on Friday, reaching $17.52. 345,323 shares of the company's stock were exchanged, compared to its average volume of 594,628. The business's fifty day simple moving average is $19.61 and its 200 day simple moving average is $21.24. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29. The firm has a market capitalization of $1.92 billion, a PE ratio of -6.74 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. On average, sell-side analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.